Literature DB >> 3591690

Effects of milrinone on complex ventricular arrhythmias in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

P L Ludmer, D S Baim, E M Antman, D F Gauthier, M B Rocco, P L Friedman, W S Colucci.   

Abstract

To determine whether oral milrinone therapy has an effect on complex ventricular arrhythmias in patients with severe congestive heart failure and, if so, whether a change in the severity of complex ventricular arrhythmias after 1 week of milrinone therapy is associated with a change in the mode or frequency of cardiac mortality, a retrospective analysis was performed to determine the frequency of ventricular tachycardia and the density of ventricular couplets on 24-hour ambulatory electrocardiographic recordings performed before and 1 week after initiation of oral milrinone therapy in 74 consecutive patients with New York Heart Association functional class III or IV congestive heart failure. The endpoints of mortality and mode of death were assessed during a mean follow-up of 6 months. In 91% of the patients, 1 week of oral milrinone therapy was associated with no significant change (85%) or a significant decrease (6%) in the density of ventricular couplets and frequency of ventricular tachycardia. However, in 9% of patients the frequency of complex ventricular arrhythmias increased significantly at the end of 1 week of oral milrinone therapy. In this subgroup, neither total cardiac mortality nor the incidence of sudden cardiac death was significantly higher than that in patients with no change or a decrease in complex ventricular ectopic activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3591690     DOI: 10.1016/0002-9149(87)90918-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Milrinone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  R A Young; A Ward
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 2.  Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.

Authors:  T A Fischer; R Erbel; N Treese
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

3.  OPC-8212 in the treatment of congestive heart failure: results of a pilot study.

Authors:  S H Kubo; T S Rector; J E Strobeck; J N Cohn
Journal:  Cardiovasc Drugs Ther       Date:  1988-12       Impact factor: 3.727

Review 4.  Phosphodiesterase III inhibitors: long-term risks and short-term benefits.

Authors:  J M Cruickshank
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.